Bone Biologics

BBLG46

Penny Stock

$1.29arrow_drop_up5.88%$0.07

Penny Stock

BBLG46

$1.29

arrow_drop_up5.88%$0.07

Penny Stock

Performance History

Key Stats
Open	$1.21
Prev. Close	$1.19
EPS	-17.24
Dividend	Non-Dividend
Next Earnings Date	-
Dividend Yield %	-
Market Cap	$2.49M
PE Ratio	-

	LOW	HIGH
Day Range	1.21	1.28
52 Week Range	0.80	10.56

Ratios

Revenue	-



EBITDA Margin %	-

EPS	-17.24

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

About Bone Biologics (BBLG)

Bone Biologics Corp (BBLG) is a biotechnology company focused on developing and commercializing orthobiologic products for the treatment of bone and joint disorders. The company's lead product candidate, NELL-1, is a novel protein that has shown promising results in preclinical and early clinical studies. NELL-1 has the potential to revolutionize the treatment of spinal fusion and other bone-related conditions, providing patients with more effective and less invasive options.

Bone Biologics Corp (BBLG) stock has had a volatile price history, with significant fluctuations over the past few years. The stock has experienced both periods of strong growth and periods of decline, reflecting the inherent risks and uncertainties of the biotechnology industry. It is important for investors to carefully consider the company's financial position, product pipeline, and market potential before making any investment decisions.

Websitecall_made

Sector: Healthcare
Industry: Medical Devices
CEO: Mr. Jeffrey Frelick
Headquarters: Burlington
Employees: 2
Exchange: NASDAQ

Keep an eye on Bone Biologics

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

What is Bone Biologics's (BBLG) price per share?

The current price per share for Bone Biologics (BBLG) is $1.29. The stock has seen a price change of $0.07 recently, indicating a 5.88% change. This reflects the stock's recent market performance and investor sentiment.

help

What is the 52-week high and low for Bone Biologics (BBLG)?

For Bone Biologics (BBLG), the 52-week high is $10.56, which is 718.6% from the current price. The 52-week low is $0.8, the current price is 61.25% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

Is Bone Biologics (BBLG) a growth stock?

Bone Biologics (BBLG) has shown an average price growth of -6.8% over the past three years. It has received a score of 17 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Bone Biologics as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

What is Bone Biologics (BBLG) stock price performance year to date (YTD)?

As of the latest data, Bone Biologics (BBLG) has a year-to-date price change of -68.84%. Over the past month, the stock has experienced a price change of -36.14%. Over the last three months, the change has been -11.03%. Over the past six months, the figure is -29.12%.

help

Is Bone Biologics (BBLG) a profitable company?

Bone Biologics (BBLG) has a net income of -$8.95M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 0% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , although specific revenue growth data is currently not available. Operating income is noted at -$9.43M. Furthermore, the EBITDA is $0.

help

What is the market capitalization of Bone Biologics (BBLG)?

Bone Biologics (BBLG) has a market capitalization of $2.68M. The average daily trading volume is 1.26, indicating the stock's liquidity and investor engagement.